Media Outlets Continue Coverage Of GSK Experimental TB Vaccine Clinical Trial Results

CIDRAP News: TB vaccine candidate shows sustained protection
“In a promising development that seems to put the world a step closer to a better vaccine against tuberculosis (TB), researchers [Tuesday] published final results from a phase 2b trial, which showed nearly 50% protection against progression to active TB. The findings confirm earlier results first reported in 2018 for the adjuvanted subunit vaccine (M72/AS01E) developed by GlaxoSmithKline (GSK) and the International AIDS Vaccine Initiative (IAVI). Researchers published their findings [Tuesday] in the New England Journal of Medicine and presented them at the 50th Union World Congress on Lung Health in Hyderabad, India…” (Schnirring, 10/29).

Additional coverage of the trial results is available from The BMJ, MedPage Today, and Science Speaks.

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.